Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Argenica Therapeutics Ltd banner

Argenica Therapeutics Ltd
ASX:AGN

Watchlist Manager
Argenica Therapeutics Ltd Logo
Argenica Therapeutics Ltd
ASX:AGN
Watchlist
Price: 0.285 AUD 9.62% Market Closed
Market Cap: AU$36.6m
Write Note Create Alert Ask AI

Argenica Therapeutics Ltd
Investor Relations

Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.

Show more
Loading
AGN
S&P/ASX 300
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.
CEO, MD & Director
No Bio Available
Ms. Emma Waldon
CFO & Company Secretary
No Bio Available
Prof. Bruno Philip Meloni
Chief Scientific Officer
No Bio Available

Contacts

Address
WESTERN AUSTRALIA
Nedlands
4/117 Broadway
Contacts
+893293396.0
argenica.com.au
sparklesyt

See Also

Summary
AGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGN stock valuation using valuation multiples.
Wall Street Estimates
AGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.